Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy

Sourat Darabi; Tolulope Adeyelu; Andrew Elliott; Ammar Sukari; Kurt Hodges; Farah Abdulla; Carlos E Zuazo; Trisha Wise-Draper; Thomas Wang; Michael J Demeure

doi:10.1097/XCS.0000000000001098

Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy

J Am Coll Surg. 2024 Apr 23. doi: 10.1097/XCS.0000000000001098. Online ahead of print.

Authors

Affiliations

¹ Hoag Memorial Hospital, Newport Beach, CA, Cancer Institute.
² Caris Life Science, Phoenix, AZ, Clinical and Translational Research.
³ Karmanos Cancer Institute, Detroit, MI, Department of Oncology.
⁴ University of Cincinnati, Cincinnati, OH, Division of Hematology/Oncology.
⁵ Translational Genomics Research Institute, Phoenix, AZ, Division of Integrated Cancer Genomics.

PMID: 38651727
DOI: 10.1097/XCS.0000000000001098

Abstract

Background: About 75% of medullary thyroid cancers (MTCs) are sporadic with 45-70% being driven by a RET mutation. Selpercatinib is an approved treatment for RET-mutated (mutRET) MTC, however, treatments are needed for wild-type RET MTC (wtRET). Genomic alterations and transcriptomic signatures of wtRET MTC may reveal new therapeutic insights.

Methods: We did a retrospective analysis of MTC samples submitted for DNA/RNA sequencing and PD-L1 expression using IHC at a CLIA/CAP-certified lab. Tumor microenvironment immune cell fractions were estimated using RNA deconvolution (quanTIseq). Transcriptomic signatures of inflammation and MAP kinase pathway activation scores (MPAS) were calculated. Mann-Whitney U, chi-square, and Fisher exact tests were applied (p-values adjusted for multiple comparisons).

Results: The 160-patient cohort included 108 mutRET and 52 wtRET MTC samples. wtRET tumors frequently harbored MAPK pathway mutations, including HRAS (42.31%), KRAS (15.7%), NF1 (6.7%), and BRAF (2%) whereas only one MAPK pathway mutation (NF1) was identified among mutRET MTC. Recurrent mutations seen in wtRET MTC included MGA, VHL, APC, STK11, and NFE2L2. Increased transcriptional activation of the MAPK pathway was observed in wtRET patients harboring mutations in MAPK genes. While the frequency of PD-L1 expression was similar in wtRET and mutRET (10.2% vs 7.0%, p=0.531), wtRET tumors were more often TMB-high (7.7% vs 0.0%, p=0.011), and wtRET MTC exhibited higher expression of immune checkpoint genes.

Conclusions: We identified molecular alterations and immune-related features that distinguish wtRET from mutRET MTC. While RET mutation drives MTC in the absence of other alterations, we showed that wtRET MTC frequently harbors MAPK pathway mutations. These findings may indicate a potential basis for MAPK-targeted therapy, possibly in combination with oncology immune-oncology agents for selected patients with wtRET MTC.